Financhill
Sell
39

LUNG Quote, Financials, Valuation and Earnings

Last price:
$6.16
Seasonality move :
4.23%
Day range:
$5.81 - $6.31
52-week range:
$5.46 - $14.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.01x
P/B ratio:
2.59x
Volume:
329.8K
Avg. volume:
230.8K
1-year change:
-49.09%
Market cap:
$243.2M
Revenue:
$68.7M
EPS (TTM):
-$1.47

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LUNG
Pulmonx
$20.3M -$0.44 15.63% -24.71% --
CUTR
Cutera
$32M -$0.96 -28.73% -56.83% --
ELMD
Electromed
$13.5M -- 11.77% -- --
IRIX
IRIDEX
$12.8M -$0.12 -2.72% -18.18% --
MYO
Myomo
$8.1M -$0.04 108.09% -69.04% $7.04
STXS
Stereotaxis
$7.1M -$0.05 40.75% -8.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LUNG
Pulmonx
$6.16 -- $243.2M -- $0.00 0% 3.01x
CUTR
Cutera
$0.36 -- $7.3M -- $0.00 0% 0.05x
ELMD
Electromed
$27.73 -- $234.5M 38.51x $0.00 0% 4.33x
IRIX
IRIDEX
$1.64 -- $27.3M -- $0.00 0% 0.55x
MYO
Myomo
$6.12 $7.04 $185.1M -- $0.00 0% 8.94x
STXS
Stereotaxis
$2.35 -- $199.1M -- $0.00 0% 7.87x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LUNG
Pulmonx
28.39% 1.298 11.37% 6.56x
CUTR
Cutera
250.93% -2.985 2641.48% 1.68x
ELMD
Electromed
-- 1.671 -- 4.99x
IRIX
IRIDEX
51.25% 1.282 9.47% 0.73x
MYO
Myomo
-- 3.291 -- 1.48x
STXS
Stereotaxis
-- 2.318 -- 0.90x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LUNG
Pulmonx
$15M -$14.1M -38.81% -51.95% -64.07% -$7.7M
CUTR
Cutera
$1.8M -$36.2M -62.63% -- -109.09% -$24.9M
ELMD
Electromed
$11.5M $1.9M 15.62% 15.62% 13.21% $2.3M
IRIX
IRIDEX
$4.3M -$1.9M -146.36% -157.91% -16.15% -$3.1M
MYO
Myomo
$6.9M -$957.6K -84.04% -84.04% -10.4% -$1.8M
STXS
Stereotaxis
$4.1M -$6.3M -108.68% -108.68% -69% -$4.3M

Pulmonx vs. Competitors

  • Which has Higher Returns LUNG or CUTR?

    Cutera has a net margin of -69.38% compared to Pulmonx's net margin of -120.06%. Pulmonx's return on equity of -51.95% beat Cutera's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    LUNG
    Pulmonx
    73.7% -$0.36 $131.2M
    CUTR
    Cutera
    5.58% -$1.94 $167.5M
  • What do Analysts Say About LUNG or CUTR?

    Pulmonx has a consensus price target of --, signalling upside risk potential of 93.45%. On the other hand Cutera has an analysts' consensus of -- which suggests that it could grow by 449.9%. Given that Cutera has higher upside potential than Pulmonx, analysts believe Cutera is more attractive than Pulmonx.

    Company Buy Ratings Hold Ratings Sell Ratings
    LUNG
    Pulmonx
    0 0 0
    CUTR
    Cutera
    0 0 0
  • Is LUNG or CUTR More Risky?

    Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cutera has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.313%.

  • Which is a Better Dividend Stock LUNG or CUTR?

    Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cutera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Cutera pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LUNG or CUTR?

    Pulmonx quarterly revenues are $20.4M, which are smaller than Cutera quarterly revenues of $32.5M. Pulmonx's net income of -$14.1M is higher than Cutera's net income of -$39M. Notably, Pulmonx's price-to-earnings ratio is -- while Cutera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.01x versus 0.05x for Cutera. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LUNG
    Pulmonx
    3.01x -- $20.4M -$14.1M
    CUTR
    Cutera
    0.05x -- $32.5M -$39M
  • Which has Higher Returns LUNG or ELMD?

    Electromed has a net margin of -69.38% compared to Pulmonx's net margin of 10.05%. Pulmonx's return on equity of -51.95% beat Electromed's return on equity of 15.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    LUNG
    Pulmonx
    73.7% -$0.36 $131.2M
    ELMD
    Electromed
    78.34% $0.16 $41.5M
  • What do Analysts Say About LUNG or ELMD?

    Pulmonx has a consensus price target of --, signalling upside risk potential of 93.45%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 19.01%. Given that Pulmonx has higher upside potential than Electromed, analysts believe Pulmonx is more attractive than Electromed.

    Company Buy Ratings Hold Ratings Sell Ratings
    LUNG
    Pulmonx
    0 0 0
    ELMD
    Electromed
    0 0 0
  • Is LUNG or ELMD More Risky?

    Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

  • Which is a Better Dividend Stock LUNG or ELMD?

    Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LUNG or ELMD?

    Pulmonx quarterly revenues are $20.4M, which are larger than Electromed quarterly revenues of $14.7M. Pulmonx's net income of -$14.1M is lower than Electromed's net income of $1.5M. Notably, Pulmonx's price-to-earnings ratio is -- while Electromed's PE ratio is 38.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.01x versus 4.33x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LUNG
    Pulmonx
    3.01x -- $20.4M -$14.1M
    ELMD
    Electromed
    4.33x 38.51x $14.7M $1.5M
  • Which has Higher Returns LUNG or IRIX?

    IRIDEX has a net margin of -69.38% compared to Pulmonx's net margin of -16.69%. Pulmonx's return on equity of -51.95% beat IRIDEX's return on equity of -157.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    LUNG
    Pulmonx
    73.7% -$0.36 $131.2M
    IRIX
    IRIDEX
    37.33% -$0.12 $5.4M
  • What do Analysts Say About LUNG or IRIX?

    Pulmonx has a consensus price target of --, signalling upside risk potential of 93.45%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 21.95%. Given that Pulmonx has higher upside potential than IRIDEX, analysts believe Pulmonx is more attractive than IRIDEX.

    Company Buy Ratings Hold Ratings Sell Ratings
    LUNG
    Pulmonx
    0 0 0
    IRIX
    IRIDEX
    0 0 0
  • Is LUNG or IRIX More Risky?

    Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IRIDEX has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.837%.

  • Which is a Better Dividend Stock LUNG or IRIX?

    Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LUNG or IRIX?

    Pulmonx quarterly revenues are $20.4M, which are larger than IRIDEX quarterly revenues of $11.6M. Pulmonx's net income of -$14.1M is lower than IRIDEX's net income of -$1.9M. Notably, Pulmonx's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.01x versus 0.55x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LUNG
    Pulmonx
    3.01x -- $20.4M -$14.1M
    IRIX
    IRIDEX
    0.55x -- $11.6M -$1.9M
  • Which has Higher Returns LUNG or MYO?

    Myomo has a net margin of -69.38% compared to Pulmonx's net margin of -10.5%. Pulmonx's return on equity of -51.95% beat Myomo's return on equity of -84.04%.

    Company Gross Margin Earnings Per Share Invested Capital
    LUNG
    Pulmonx
    73.7% -$0.36 $131.2M
    MYO
    Myomo
    75.43% -$0.03 $9.3M
  • What do Analysts Say About LUNG or MYO?

    Pulmonx has a consensus price target of --, signalling upside risk potential of 93.45%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 25.27%. Given that Pulmonx has higher upside potential than Myomo, analysts believe Pulmonx is more attractive than Myomo.

    Company Buy Ratings Hold Ratings Sell Ratings
    LUNG
    Pulmonx
    0 0 0
    MYO
    Myomo
    4 0 0
  • Is LUNG or MYO More Risky?

    Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

  • Which is a Better Dividend Stock LUNG or MYO?

    Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LUNG or MYO?

    Pulmonx quarterly revenues are $20.4M, which are larger than Myomo quarterly revenues of $9.2M. Pulmonx's net income of -$14.1M is lower than Myomo's net income of -$966.4K. Notably, Pulmonx's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.01x versus 8.94x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LUNG
    Pulmonx
    3.01x -- $20.4M -$14.1M
    MYO
    Myomo
    8.94x -- $9.2M -$966.4K
  • Which has Higher Returns LUNG or STXS?

    Stereotaxis has a net margin of -69.38% compared to Pulmonx's net margin of -67.31%. Pulmonx's return on equity of -51.95% beat Stereotaxis's return on equity of -108.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    LUNG
    Pulmonx
    73.7% -$0.36 $131.2M
    STXS
    Stereotaxis
    44.57% -$0.08 $16.2M
  • What do Analysts Say About LUNG or STXS?

    Pulmonx has a consensus price target of --, signalling upside risk potential of 93.45%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 91.49%. Given that Pulmonx has higher upside potential than Stereotaxis, analysts believe Pulmonx is more attractive than Stereotaxis.

    Company Buy Ratings Hold Ratings Sell Ratings
    LUNG
    Pulmonx
    0 0 0
    STXS
    Stereotaxis
    0 0 0
  • Is LUNG or STXS More Risky?

    Pulmonx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

  • Which is a Better Dividend Stock LUNG or STXS?

    Pulmonx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pulmonx pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LUNG or STXS?

    Pulmonx quarterly revenues are $20.4M, which are larger than Stereotaxis quarterly revenues of $9.2M. Pulmonx's net income of -$14.1M is lower than Stereotaxis's net income of -$6.2M. Notably, Pulmonx's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pulmonx is 3.01x versus 7.87x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LUNG
    Pulmonx
    3.01x -- $20.4M -$14.1M
    STXS
    Stereotaxis
    7.87x -- $9.2M -$6.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 0.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.55% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock